{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T12:14:50Z","timestamp":1789560890034,"version":"build-2803163510"},"reference-count":96,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosglobalpublichealth.org"],"crossmark-restriction":false},"short-container-title":["PLOS Glob Public Health"],"abstract":"<jats:p>New health products have contributed to major improvements in public health, but many clinically effective interventions still face delays in reaching low- and middle-income countries (LMICs). Market shaping approaches have emerged as a set of tools designed to address such access gaps by influencing prices, supply, and demand. Drawing on practitioner experience and illustrative cases, this paper examines how market shaping mechanisms have been used to expand access to pharmaceutical products in LMICs. We review examples including dolutegravir, rifapentine-based tuberculosis preventive therapy, pretomanid for drug-resistant tuberculosis, the RTS,S malaria vaccine, and Rwanda\u2019s hepatitis C program, alongside ecosystem-level interventions such as revolving funds and initiatives to strengthen regional manufacturing. Across these cases, we suggest generalizable lessons and describe trade-offs related to donor dependence, supplier concentration, and timing of interventions. The paper identifies priorities for empirical research to assess the performance, risks, and applicability of market shaping tools as global health needs and resource environments evolve.<\/jats:p>","DOI":"10.1371\/journal.pgph.0004523","type":"journal-article","created":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:21:47Z","timestamp":1771957307000},"page":"e0004523","update-policy":"https:\/\/doi.org\/10.1371\/journal.pgph.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Advancing global health access through market shaping: Cases and learnings"],"prefix":"10.1371","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5886-4130","authenticated-orcid":true,"given":"Claire M.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8816-0777","authenticated-orcid":true,"given":"Amy","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabin","family":"Nsanzimana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet K.","family":"Ginnard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayasree K.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3906-5168","authenticated-orcid":true,"given":"Mary-Ann","family":"Etiebet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ripin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3735-3120","authenticated-orcid":true,"given":"Sandeep","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Hein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9630-5866","authenticated-orcid":true,"given":"Gian","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7924-6761","authenticated-orcid":true,"given":"Charles B.","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,2,24]]},"reference":[{"issue":"2","key":"pgph.0004523.ref001","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1473-3099(21)00458-8","article-title":"Polio eradication: what kind of world do we want?","volume":"22","author":"KM Thompson","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"pgph.0004523.ref002","unstructured":"UNAIDS. The path that ends AIDS. 2023. Available at: https:\/\/thepath.unaids.org\/wp-content\/themes\/unaids2023\/assets\/files\/2023_report.pdf"},{"issue":"6","key":"pgph.0004523.ref003","article-title":"Development, launch, and scale-up of health products in low-income and middle-income countries: a retrospective analysis on 59 health products","volume":"13","author":"W Mao","year":"2025","journal-title":"Lancet Glob Health"},{"issue":"9","key":"pgph.0004523.ref004","article-title":"A comprehensive framework identifying barriers to global health R&D innovation and access","volume":"8","author":"M Ong","year":"2023","journal-title":"BMJ Glob Health"},{"issue":"1","key":"pgph.0004523.ref005","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-014425","article-title":"Shaping the future of global access to safe, effective, appropriate and quality health products","volume":"9","author":"R Ravinetto","year":"2024","journal-title":"BMJ Glob Health"},{"issue":"10","key":"pgph.0004523.ref006","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1377\/hlthaff.2024.00089","article-title":"Low- And Middle-Income Countries Experienced Delays Accessing New Essential Medicines, 1982-2024","volume":"43","author":"OJ Wouters","year":"2024","journal-title":"Health Aff (Millwood)"},{"issue":"1","key":"pgph.0004523.ref007","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1257\/aer.20141482","article-title":"Patents and the Global Diffusion of New Drugs","volume":"106","author":"IM Cockburn","year":"2016","journal-title":"Am Econ Rev"},{"issue":"11","key":"pgph.0004523.ref008","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1007\/s40273-021-01065-y","article-title":"How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment","volume":"39","author":"M Schlander","year":"2021","journal-title":"Pharmacoeconomics"},{"issue":"9","key":"pgph.0004523.ref009","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","volume":"323","author":"OJ Wouters","year":"2020","journal-title":"JAMA"},{"issue":"7","key":"pgph.0004523.ref010","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1093\/heapol\/czs108","article-title":"Access to medicines from a health system perspective","volume":"28","author":"M Bigdeli","year":"2013","journal-title":"Health Policy Plan"},{"issue":"10067","key":"pgph.0004523.ref011","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0140-6736(16)31599-9","article-title":"Essential medicines for universal health coverage","volume":"389","author":"VJ Wirtz","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"pgph.0004523.ref012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001218","article-title":"Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system?","volume":"9","author":"S Moon","year":"2012","journal-title":"PLoS Med"},{"key":"pgph.0004523.ref013","volume-title":"Market shaping for access to medical products: a practical guide","author":"Organization World Health","year":"2021"},{"key":"pgph.0004523.ref014","unstructured":"Gavi, the Vaccine Alliance. Gavi market shaping approach. Geneva: Gavi, the Vaccine Alliance. 2018."},{"key":"pgph.0004523.ref015","unstructured":"Clinton Health Access Initiative. Market shaping primer. Boston, MA: Clinton Health Access Initiative. 2020."},{"issue":"6743","key":"pgph.0004523.ref016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1126\/science.ady0874","article-title":"No one can replace the U.S. as it retreats from global health","volume":"388","author":"I Jooste","year":"2025","journal-title":"Science"},{"issue":"6","key":"pgph.0004523.ref017","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41587-021-00942-3","article-title":"The need for global access to biomedical innovations during pandemics","volume":"39","author":"R Gupta","year":"2021","journal-title":"Nat Biotechnol"},{"key":"pgph.0004523.ref018","unstructured":"Consortium of Universities for Global Health. Market shaping and global health: Accelerating access to novel pharmaceutical products worldwide. Available at: https:\/\/static1.squarespace.com\/static\/6298f70d5e12f455136a80a7\/t\/6436bb05b645b20d4acb742a\/1681308422639\/FINAL+Conference+Program+Agenda.pdf#h.s53k4qsi13wi"},{"issue":"10037","key":"pgph.0004523.ref019","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1016\/S0140-6736(16)30168-4","article-title":"Development assistance for health: past trends, associations, and the future of international financial flows for health","volume":"387","author":"JL Dieleman","year":"2016","journal-title":"Lancet"},{"issue":"9","key":"pgph.0004523.ref020","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(25)00232-3","article-title":"The potential impact of reductions in international donor funding on tuberculosis in low-income and middle-income countries: a modelling study","volume":"13","author":"RA Clark","year":"2025","journal-title":"Lancet Glob Health"},{"key":"pgph.0004523.ref021","unstructured":"USAID Center for Innovation and Impact. Healthy Markets for Global Health: A Market Shaping Primer. Available at: https:\/\/www.usaid.gov\/cii\/market-shaping-primer"},{"key":"pgph.0004523.ref022","unstructured":"Market Shaping Strategy. 34th Board Meeting Market Shaping Strategy. 2015, November 15. https:\/\/archive.theglobalfund.org\/media\/4200\/archive_bm34-17-annex1marketshapingstrategy_paper_en.pdf"},{"key":"pgph.0004523.ref023","unstructured":"Gavi. Market Shaping 2024. Available at: https:\/\/www.gavi.org\/our-alliance\/market shaping"},{"key":"pgph.0004523.ref024","unstructured":"Gavi Alliance Market Shaping Strategy 2021-2025. Available at: https:\/\/www.gavi.org\/sites\/default\/files\/about\/Gavi-Alliance-Market shaping-Strategy-2021-2025.pdf"},{"key":"pgph.0004523.ref025","unstructured":"Untaid. Unitaid Strategy 2023-2027. Available at: https:\/\/unitaid.org\/assets\/Unitaid_Strategy_2023-2027.pdf"},{"key":"pgph.0004523.ref026","unstructured":"CHAI. CHAI Market Shaping Framework. 2024. https:\/\/www.clintonhealthaccess.org\/wp-content\/uploads\/2024\/02\/CHAI-Market%20shaping-Framework-Feb2024.pdf"},{"key":"pgph.0004523.ref027","unstructured":"MedAccess. Our Innovative Finance Products. Available at: https:\/\/medaccess.org\/innovative-finance\/our-innovative-finance-products\/"},{"key":"pgph.0004523.ref028","doi-asserted-by":"crossref","unstructured":"Gehl Sampath, Padmashree, Market Shaping and Market Access in the Global Vaccines Market: Approaches for the Future (October 02, 2021). Available at SSRN: https:\/\/ssrn.com\/abstract=3945668","DOI":"10.2139\/ssrn.3945668"},{"issue":"2","key":"pgph.0004523.ref029","doi-asserted-by":"crossref","first-page":"142","DOI":"10.4161\/23288604.2014.968005","article-title":"Health Product Supply Chains in Developing Countries: Diagnosis of the Root Causes of Underperformance and an Agenda for Reform","volume":"1","author":"P Yadav","year":"2015","journal-title":"Health Syst Reform"},{"issue":"3","key":"pgph.0004523.ref030","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1001\/jama.2010.993","article-title":"Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs","volume":"304","author":"CB Holmes","year":"2010","journal-title":"JAMA"},{"issue":"3","key":"pgph.0004523.ref031","article-title":"Analyzing global health access architecture: pathways for equitable product availability","volume":"7","author":"S Moon","year":"2022","journal-title":"BMJ Glob Health"},{"issue":"3","key":"pgph.0004523.ref032","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/17512433.2020.1724782","article-title":"The European Medicines Agency facilitates access to medicines in low- and middle-income countries","volume":"13","author":"M Cavaller Bellaubi","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"7","key":"pgph.0004523.ref033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgph.0003418","article-title":"Novel approaches to enable equitable access to monoclonal antibodies in low- and middle-income countries","volume":"4","author":"S Malhotra","year":"2024","journal-title":"PLOS Glob Public Health"},{"issue":"24","key":"pgph.0004523.ref034","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1016\/j.vaccine.2018.03.049","article-title":"Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes","volume":"36","author":"N Dellepiane","year":"2018","journal-title":"Vaccine"},{"issue":"6","key":"pgph.0004523.ref035","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1007\/s10995-014-1636-3","article-title":"New dialogue for the way forward in maternal health: addressing market inefficiencies","volume":"19","author":"K McCarthy","year":"2015","journal-title":"Matern Child Health J"},{"key":"pgph.0004523.ref036","unstructured":"Kudymowa J, Hu J, Basnak M. An overview of market shaping for global health: landscape, new developments, and gaps. Rethink Priorities. September 2023. Accessed March 18, 2025. https:\/\/rethinkpriorities.org\/wp-content\/uploads\/2023\/09\/An-overview-of-marketshaping-in-global-health-Landscape-new-developments-and-gaps.pdf"},{"key":"pgph.0004523.ref037","unstructured":"Teo M. How do advance market commitments and volume guarantees shape healthcare markets? MedAccess. November 30, 2023. Accessed March 18, 2025. https:\/\/medaccess.org\/how-do-advance-market-commitments-and-volume-guarantees-shape-healthcare-markets\/"},{"key":"pgph.0004523.ref038","unstructured":"Center for Accelerating Innovation and Impact. 2014. Healthy markets for global health: A market shaping primer. United States Agency for International Development. https:\/\/perma.cc\/M4RD-KTC4"},{"key":"pgph.0004523.ref039","doi-asserted-by":"crossref","unstructured":"Mao W, Olson K, Urli Hodges E, Udayakumar K. Progress, Impacts and Lessons from Market Shaping in the Past Decade: A Systematic Review. Available at SSRN: https:\/\/ssrn.com\/abstract=4726177 or http:\/\/dx.doi.org\/10.2139\/ssrn.4726177","DOI":"10.2139\/ssrn.4726177"},{"issue":"4","key":"pgph.0004523.ref040","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S2055-6640(20)30311-3","article-title":"Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries","volume":"4","author":"J Sim","year":"2018","journal-title":"J Virus Erad"},{"key":"pgph.0004523.ref041","unstructured":"Special Edition Report Dolutegravir. Initiative for Medicine Access & Knowledge. Available at: http:\/\/www.i-mak.org\/wp-content\/uploads\/2017\/06\/I-MAKRoadmapSEReportDTG20170619F.pdf"},{"key":"pgph.0004523.ref042","unstructured":"UNITAID. UNITAID Strategy Review 2017-2021. Available at: https:\/\/unitaid.org\/assets\/Unitaid-2017-2021-Strategy-Review_Final-Report_Vol-2-Annexes.pdf"},{"key":"pgph.0004523.ref043","unstructured":"Clinton Health Access Initiative. New high-quality antiretroviral therapy to be launched in South Africa, Kenya and over 90 low- and middle-income countries at reduced price. Available at: https:\/\/www.clintonhealthaccess.org\/news\/new-high-quality-antiretroviral-therapy-launched-south-africa-kenya-90-low-middle-income-countries-reduced-price\/"},{"key":"pgph.0004523.ref044","unstructured":"PR Newswire. Viatris Inc. Announces FDA Tentative Approval of a Pediatric Formulation of Dolutegravir (DTG) Under PEPFAR. Available at: https:\/\/www.prnewswire.com\/news-releases\/viatris-inc-announces-fda-tentative-approval-of-a-pediatric-formulation-of-dolutegravir-dtg-under-pepfar-301179208.html"},{"key":"pgph.0004523.ref045","unstructured":"Clinton Health Access Initiative. Prioritizing pediatrics: accelerating access to optimal pediatric HIV treatment. Boston: CHAI; 2021 Dec. Available from: https:\/\/www.clintonhealthaccess.org\/report\/prioritizing-pediatrics\/"},{"key":"pgph.0004523.ref046","unstructured":"Medicines Patent Pool. MPP Impact Analysis: HIV (2012-2018). Available at: https:\/\/medicinespatentpool.org\/uploads\/2019\/07\/DTG-Impact-Analysis_June19.pdf"},{"key":"pgph.0004523.ref047","unstructured":"World Health Organization. Update on the transition to dolutegravir-based antiretroviral therapy. 2022. Available at: https:\/\/www.who.int\/publications-detail-redirect\/9789240053335"},{"issue":"1","key":"pgph.0004523.ref048","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12992-022-00851-3","article-title":"\u201cNo Regrets\u201d Purchasing in a pandemic: making the most of advance purchase agreements","volume":"18","author":"I Thornton","year":"2022","journal-title":"Global Health"},{"issue":"23","key":"pgph.0004523.ref049","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"TR Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"10","key":"pgph.0004523.ref050","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1097\/QAD.0000000000001098","article-title":"Three months of weekly rifapentine and isoniazid for treatment of Mycobacterium tuberculosis infection in HIV-coinfected persons","volume":"30","author":"TR Sterling","year":"2016","journal-title":"AIDS"},{"issue":"11","key":"pgph.0004523.ref051","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis","volume":"380","author":"S Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"pgph.0004523.ref052","unstructured":"Unitaid. Partners announce reduced price for patient-friendly tuberculosis preventive treatments. Available at: https:\/\/unitaid.org\/news-blog\/tb-preventive-therapy\/#en"},{"key":"pgph.0004523.ref053","unstructured":"MedAccess. Improving availability of patient-friendly tuberculosis preventive therapy. Available at: https:\/\/medaccess.org\/improving-availability-of-patient-friendly-tuberculosis-preventive-therapy\/"},{"key":"pgph.0004523.ref054","unstructured":"Unitaid. Partners announce reduced price for patient-friendly tuberculosis preventive treatments. Available at: https:\/\/unitaid.org\/news-blog\/tb-preventive-therapy\/#en"},{"key":"pgph.0004523.ref055","unstructured":"TAG. New Rifapentine Formulations at New Prices: No Excuses for Not Scaling-Up TB Preventive Treatment. Available at: https:\/\/www.treatmentactiongroup.org\/statement\/new-rifapentine-formulations-at-new-prices-no-excuses-for-not-scaling-up-tb-preventive-treatment\/"},{"key":"pgph.0004523.ref056","unstructured":"TB alliance applauds Macleods\u2019 launch of a key component of WHO-recommended drug-resistant TB treatment regimen. TB Alliance. Available at: https:\/\/www.tballiance.org\/news\/tb-alliance-applauds-macleods-launch-key-component-who-recommended-drug-resistant-tb-treatment"},{"issue":"10","key":"pgph.0004523.ref057","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"F Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"pgph.0004523.ref058","unstructured":"Access to Medicine Foundation. Viatris leads in strategies to expand access to TB treatment (pretomanid). Available at: https:\/\/accesstomedicinefoundation.org\/resource\/viatris-leads-in-strategies-to-expand-access-to-tb-treatment-pretomanid"},{"key":"pgph.0004523.ref059","unstructured":"TB Alliance. Realizing our \u201cTriple-A Mandate. https:\/\/www.tballiance.org.za\/news\/realizing-our-triple-a-mandate"},{"key":"pgph.0004523.ref060","unstructured":"MedAccess, Viatris and TB Alliance. Price reduction paves the way for expanded access to highly effective multidrug-resistant tuberculosis treatment. Available at: https:\/\/medaccess.org\/price-reduction-paves-the-way-for-expanded-access-to-highly-effective-multidrug-resistant-tuberculosis-treatment\/"},{"key":"pgph.0004523.ref061","unstructured":"TBCAB. TB Alliance applauds Macleods\u2019 launch of a key component of WHO-recommended drug-resistant TB treatment regimen. https:\/\/www.tbonline.info\/posts\/2023\/11\/13\/tb-alliance-applauds-macleods-launch-key-component\/"},{"key":"pgph.0004523.ref062","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.jvacx.2019.100033","article-title":"Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market","volume":"2","author":"M Malhame","year":"2019","journal-title":"Vaccine X"},{"issue":"4","key":"pgph.0004523.ref063","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-014719","article-title":"Policy uptake and implementation of the RTS,S\/AS01 malaria vaccine in sub-Saharan African countries: status 2 years following the WHO recommendation","volume":"9","author":"CB Osoro","year":"2024","journal-title":"BMJ Glob Health"},{"key":"pgph.0004523.ref064","unstructured":"PATH. Developing the world\u2019s first malaria vaccine (RTS,S). (2024). https:\/\/www.path.org\/our-impact\/case-studies\/developing-the-worlds-first-malaria-vaccine-rtss\/"},{"key":"pgph.0004523.ref065","unstructured":"MedAccess. RTS,S malaria vaccine. (2024). https:\/\/medaccess.org\/our-agreements\/agreements\/rtss-malaria-vaccine\/"},{"key":"pgph.0004523.ref066","unstructured":"World Health Organization. 2022. WHO Guidelines for malaria. https:\/\/www.nitag-resource.org\/sites\/default\/files\/2022-05\/Full-evidence-report-on-the-rtss-as01-malaria-vaccine-2021.pdf"},{"key":"pgph.0004523.ref067","unstructured":"World Health Organization. WHO recommends groundbreaking malaria vaccine for children at risk. World Health Organization. 2021. https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk"},{"key":"pgph.0004523.ref068","unstructured":"New financing agreement boost for malaria vaccine. https:\/\/www.gavi.org\/news\/media-room\/new-financing-agreement-boost-malaria-vaccine"},{"key":"pgph.0004523.ref069","unstructured":"Gavi, WHO and UNICEF. 18 million doses of first-ever malaria vaccine allocated to 12 African countries for 2023\u20132025. Available at: https:\/\/www.who.int\/news\/item\/05-07-2023-18-million-doses-of-first-ever-malaria-vaccine-allocated-to-12-african-countries-for-2023-2025--gavi--who-and-unicef"},{"key":"pgph.0004523.ref070","unstructured":"Unitaid, M\u00e9decins S, Fronti\u00e8res. Hepatitis C: Simple and effective treatment models in low-resource settings. Geneva: Unitaid. 2017."},{"key":"pgph.0004523.ref071","article-title":"Simplifying hepatitis C treatment in resource-limited settings: real-world outcomes from community-based programs","volume":"21","author":"A Avihingsanon","year":"2018","journal-title":"J Int AIDS Soc"},{"issue":"6","key":"pgph.0004523.ref072","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jhep.2019.03.011","article-title":"Rwanda launches a 5-year national hepatitis C elimination plan: A landmark in sub-Saharan Africa","volume":"70","author":"G Umutesi","year":"2019","journal-title":"J Hepatol"},{"key":"pgph.0004523.ref073","unstructured":"World Health Organization. Eliminating hepatitis - Rwanda. World Health Organization. 2023. https:\/\/www.afro.who.int\/countries\/rwanda\/news\/eliminating-hepatitis#:~:text=Rwanda"},{"key":"pgph.0004523.ref074","unstructured":"UNICEF, WHO, IFRC and MSF announce the establishment of a global Ebola vaccine stockpile. https:\/\/www.who.int\/news\/item\/12-01-2021-unicef-who-ifrc-and-msf-announce-the-establishment-of-a-global-ebola-vaccine-stockpile"},{"issue":"5","key":"pgph.0004523.ref075","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgh-2023-012436","article-title":"Public health emergency archetypes: a framework to guide efforts to ensure equitable access to medical countermeasures","volume":"8","author":"PA Wilson","year":"2023","journal-title":"BMJ Glob Health"},{"key":"pgph.0004523.ref076","unstructured":"WHO. Ebola virus disease: Vaccines. Available at: https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/ebola-vaccines"},{"key":"pgph.0004523.ref077","unstructured":"WHO. Ebola vaccine stockpiles. Available at: https:\/\/www.who.int\/groups\/icg\/ebola-virus-disease\/ebola-stockpiles"},{"issue":"3","key":"pgph.0004523.ref078","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01627-23","article-title":"Translational success of fundamental virology: a VSV-vectored Ebola vaccine","volume":"98","author":"EM Anderson","year":"2024","journal-title":"J Virol"},{"key":"pgph.0004523.ref079","unstructured":"Merck Confirms Agreement with UNICEF to Establish the World\u2019s First Global Ebola Vaccine Stockpile with ERVEBO (Ebola Zaire Vaccine, Live) - Merck.com."},{"key":"pgph.0004523.ref080","doi-asserted-by":"crossref","DOI":"10.1093\/inthealth\/ihaa077","article-title":"The role of medicine donations in the global programme for the elimination of lymphatic filariasis","volume":"13","author":"T Williams","year":"2020","journal-title":"Int Health"},{"issue":"2","key":"pgph.0004523.ref081","doi-asserted-by":"crossref","DOI":"10.1016\/S2468-2667(21)00202-4","article-title":"The economic and public health impact of intellectual property licensing of medicines for low-income and middle-income countries: a modelling study","volume":"7","author":"S Morin","year":"2022","journal-title":"Lancet Public Health"},{"key":"pgph.0004523.ref082","unstructured":"United Nations Children\u2019s Fund (UNICEF). Extension and expansion of the Vaccine Independence Initiative and its revolving fund. E\/ICEF\/2025\/P\/L.7. New York: UNICEF; 2024. Available from: https:\/\/www.unicef.org\/executiveboard\/media\/28231\/file\/2025-PL7-Extension-vaccine-independence-EN-ODS.pdf"},{"key":"pgph.0004523.ref083","unstructured":"UNICEF. The Vaccine Independence Initiative. Available at: https:\/\/www.unicef.org\/supply\/vaccine-independence-initiative"},{"key":"pgph.0004523.ref084","unstructured":"Global Fund Announces New Mechanism to Increase Access to More Effective Mosquito Nets to Prevent Malaria. Available at: https:\/\/www.theglobalfund.org\/en\/news\/2023\/2023-08-22-global-fund-announces-new-mechanism-increase-access-more-effective-mosquito-nets-prevent-malaria\/"},{"key":"pgph.0004523.ref085","unstructured":"Partnerships for African Vaccine Manufacturing (PAVM) Framework for Action. Africa CDC. Available at: https:\/\/africacdc.org\/download\/partnerships-for-african-vaccine-manufacturing-pavm-framework-for-action\/"},{"key":"pgph.0004523.ref086","unstructured":"Africa CDC. The change in African vaccine manufacturing landscape. Available at: https:\/\/africacdc.org\/wp-content\/uploads\/2024\/11\/The-change-in-African-vaccine-manufacturing-landscape-.pdf"},{"issue":"12","key":"pgph.0004523.ref087","article-title":"The Affordable Medicines Facility\u2013malaria: achievements, challenges, and lessons learned","volume":"5","author":"I Osei-Akoto","year":"2020","journal-title":"BMJ Global Health"},{"issue":"8","key":"pgph.0004523.ref088","doi-asserted-by":"crossref","first-page":"2670","DOI":"10.1080\/21645515.2021.1874219","article-title":"Development strategy and lessons learned for a 10-valent pneumococcal conjugate vaccine (PNEUMOSIL\u00ae)","volume":"17","author":"MR Alderson","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"pgph.0004523.ref089","unstructured":"The Federal Democratic Republic of Ethiopia. Ethiopian Pharmaceutical Supply Agency Pharmaceuticals Supply Transformation Plan II (PSTP II) 2020\/21-2029\/30. Available at: http:\/\/repository.iphce.org\/handle\/123456789\/2944"},{"key":"pgph.0004523.ref090","unstructured":"Results for Development. Institutionalizing Market Shaping Capacity in Ethiopia through a Novel Systemic Approach. Available from: https:\/\/r4d.org\/projects\/institutionalizing-marketshaping-capacity-in-ethiopia-through-a-novel-systemic-approach\/"},{"key":"pgph.0004523.ref091","unstructured":"Gavi. Partnering with multilateral development banks to build sustainable immunization systems. Available at: https:\/\/www.gavi.org\/sites\/default\/files\/white-paper\/2025\/background-paper-Multilateral-development-banks_ENG.pdf"},{"key":"pgph.0004523.ref092","doi-asserted-by":"crossref","first-page":"100033","DOI":"10.1016\/j.jvacx.2019.100033","article-title":"Shaping markets to benefit global health - A 15-year history and lessons learned from the pentavalent vaccine market","volume":"2","author":"M Malhame","year":"2019","journal-title":"Vaccine X"},{"key":"pgph.0004523.ref093","doi-asserted-by":"crossref","first-page":"127012","DOI":"10.1016\/j.vaccine.2025.127012","article-title":"Challenges and lessons learned during the switching of rotavirus vaccine from Rotarix to Rotavac in Zambia","volume":"55","author":"EM Mpabalwani","year":"2025","journal-title":"Vaccine"},{"key":"pgph.0004523.ref094","first-page":"2023","volume-title":"African Medicines Regulatory Harmonization (AMRH): Progress report","author":"World Health Organization","year":"2023"},{"issue":"4","key":"pgph.0004523.ref095","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cpt.1658","article-title":"Examining the Use of Real-World Evidence in the Regulatory Process","volume":"107","author":"BK Beaulieu-Jones","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"10","key":"pgph.0004523.ref096","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003783","article-title":"Characterising the nationwide burden and predictors of unkept outpatient appointments in the National Health Service in England: A cohort study using a machine learning approach","volume":"18","author":"S Philpott-Morgan","year":"2021","journal-title":"PLoS Med"}],"container-title":["PLOS Global Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004523","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T18:22:04Z","timestamp":1771957324000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pgph.0004523"}},"subtitle":[],"editor":[{"given":"Olivier J","family":"Wouters","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,2,24]]},"references-count":96,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pgph.0004523","relation":{},"ISSN":["2767-3375"],"issn-type":[{"value":"2767-3375","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,24]]}}}